TARON FORTE- iron, calcium ascorbate, cyanocobalamin, and folic acid capsule

País: Estados Unidos

Idioma: inglés

Fuente: NLM (National Library of Medicine)

Ingredientes activos:

IRON (UNII: E1UOL152H7) (IRON - UNII:E1UOL152H7), CALCIUM ASCORBATE (UNII: 183E4W213W) (ASCORBIC ACID - UNII:PQ6CK8PD0R), CYANOCOBALAMIN (UNII: P6YC3EG204) (CYANOCOBALAMIN - UNII:P6YC3EG204), FOLIC ACID (UNII: 935E97BOY8) (FOLIC ACID - UNII:935E97BOY8)

Disponible desde:

Trigen Laboratories, LLC

Designación común internacional (DCI):

IRON

Composición:

IRON 150 mg

Vía de administración:

ORAL

indicaciones terapéuticas:

Taron Forte Capsules are contraindicated in patients with a known hypersensitivity to any of the components of this product. Hemochromatosis and hemosiderosis are contraindications to iron therapy.

Resumen del producto:

Taron Forte Capsules are packaged in child-resistant bottles of 100 capsules. PRODUCT CODE 13811-042-10.

Estado de Autorización:

Dietary Supplement

Ficha técnica

TARON FORTE- IRON, CALCIUM ASCORBATE, CYANOCOBALAMIN, AND FOLIC
ACID CAPSULE
TRIGEN LABORATORIES, LLC
----------
TARON FORTE
CAPSULES
SUPPLEMENT FACTS
Taron Forte Multivitamin/Mineral with Iron capsules are indicated for
the distinctive
nutritional requirements of persons being treated for iron
deficiencies by a physician.
CONTRAINDICATIONS
Taron Forte Capsules are contraindicated in patients with a known
hypersensitivity to
any of the components of this product.
Hemochromatosis and hemosiderosis are contraindications to iron
therapy.
WARNINGS
WARNING: ACCIDENTAL OVERDOSE OF IRON-CONTAINING PRODUCTS IS A LEADING
CAUSE OF FATAL
POISONING IN CHILDREN UNDER 6. KEEP THIS PRODUCT OUT OF REACH OF
CHILDREN. IN
CASE OF ACCIDENTAL OVERDOSE, CALL A DOCTOR OR POISON CONTROL CENTER
IMMEDIATELY.
PRECAUTIONS
GENERAL: The type of anemia and the underlying cause or causes should
be determined
before starting therapy with Taron Forte Capsules. Since the anemia
may be a result of a
systemic disturbance, such as recurrent blood loss, the underlying
cause or causes
should be corrected, if possible.
Folic acid alone is improper therapy in the treatment of pernicious
anemia and other
megaloblastic anemias where B
is deficient.
Folic acid in doses above 0.1 mg daily may obscure pernicious anemia
assessment, such
that hematologic remission can occur while neurological manifestations
remain
progressive.
PEDIATRIC USE: Safety and effectiveness of this product have not been
established in
pediatric patients.
ADVERSE REACTIONS
Adverse reactions with iron therapy may include constipation,
diarrhea, nausea,
vomiting, dark stools, and abdominal pain. Adverse reactions with iron
therapy are
usually transient. Allergic sensitization has been reported following
both oral and
parenteral administration of folic acid.
The clinical cause of acute iron overdosage can be variable. Initial
symptoms may
include: abdominal pain, nausea, vomiting, diarrhea, tarry stools,
melena, hematemesis,
hypotension, tachycardia, metabolic acidosis, hyperglycemia,
dehy